Cachexia

From Molecular Insights to Clinical Strategies: Delve into the complexities of cachexia, encompassing cancer cachexia, molecular mechanisms, and evolving therapeutic approaches. Discover the forefront of research aimed at understanding and combating this debilitating condition.

Associations of Handgrip Strength and Testosterone With Cerebral White Matter Hyperintensity and Microstructural Injury.

White matter hyperintensity (WMH) is one of the key imaging markers of cerebral small vessel disease (CSVD) and white matter microstructural injury may occur earlier than WMH. However, the associations of handgrip strength (HGS) and serum total testosterone (STT) with...

🗓️ 2025-06-01
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreAssociations of Handgrip Strength and Testosterone With Cerebral White Matter Hyperintensity and Microstructural Injury.

Body Mass Index Changes and Femur Fracture Risk in Parkinson's Disease: National Cohort Study.

Parkinson's disease (PD) increases fracture risk owing to postural instability and bone fragility, with femur fractures being the most frequent and clinically significant. Many patients with PD experience weight loss as the disease progresses, and low body mass index (BMI)...

🗓️ 2025-06-01
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreBody Mass Index Changes and Femur Fracture Risk in Parkinson's Disease: National Cohort Study.

Desensitizing Effect of Intra-Tumoral GDF-15 on Immunotherapy in Patients With Advanced Non-Small Cell Lung Cancer.

Serum growth/differentiation factor 15 (GDF-15) suppresses anti-tumor immunity and predicts prognosis in several malignancies. Elevated GDF-15 levels are linked to cancer cachexia, characterized by weight loss and systemic inflammation, adversely affecting patient outcomes and therapy response. However, serum GDF-15 is...

🗓️ 2025-05-01
📰 Publication: Thoracic Cancer
Read MoreDesensitizing Effect of Intra-Tumoral GDF-15 on Immunotherapy in Patients With Advanced Non-Small Cell Lung Cancer.

Stool Microbiome Features and Weight Change Response to Treatment for cancer cachexia.

Cancer cachexia is characterised by significant weight loss and muscle wasting that adversely affects patient outcomes. Nutritional interventions in cancer cachexia leads to improved outcomes, including improved weight change. However, there are wide variations in weight response to dietary interventions....

🗓️ 2025-06-01
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreStool Microbiome Features and Weight Change Response to Treatment for cancer cachexia.

Hepatic gluconeogenesis and PDK3 upregulation drive cancer cachexia in flies and mice.

Cachexia, a severe wasting syndrome characterized by tumour-induced metabolic dysregulation, is a leading cause of death in people with cancer, yet its underlying mechanisms remain poorly understood. Here we show that a longitudinal full-body single-nuclei-resolution transcriptome analysis in a Drosophila...

🗓️ 2025-04-16
Read MoreHepatic gluconeogenesis and PDK3 upregulation drive cancer cachexia in flies and mice.

Low Visceral Adipose Tissue Predicts the Outcome of Neoadjuvant Chemotherapy for Colorectal Liver Metastases: A Multicentre Real-World Study.

Visceral obesity (VO), associated with excessive visceral adipose tissue (VAT), has been extensively studied in cancer. However, whether low VAT can predict the prognosis of colorectal liver metastases (CRLM) undergoing neoadjuvant chemotherapy (NAC) remains unknown. This multicentre real-world cohort study...

🗓️ 2025-04-01
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreLow Visceral Adipose Tissue Predicts the Outcome of Neoadjuvant Chemotherapy for Colorectal Liver Metastases: A Multicentre Real-World Study.

A Dynamic Time Warping Extension to Consensus Weight-Based Cachexia Criteria Improves Prediction of Cancer Patient Outcomes.

Cachexia is a complex syndrome that impacts up to half of patients with cancer. Criteria systems have been developed for the purpose of diagnosing and grading cachexia severity in clinical settings. One of the most widely known is those developed...

🗓️ 2025-01-29
Read MoreA Dynamic Time Warping Extension to Consensus Weight-Based Cachexia Criteria Improves Prediction of Cancer Patient Outcomes.

A Novel Definition and Grading Diagnostic Criteria for Tumour-Type-Specific Comprehensive Cachexia Risk.

The existing diagnostic criteria for cancer cachexia do not meet clinical needs. We aimed to establish novel comprehensive evaluation scales for cachexia specific to patients with solid tumours. This study included 12 651 patients (males: 6793 [53.7%]; females: 5858 [46.3%]; medium...

🗓️ 2025-04-01
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreA Novel Definition and Grading Diagnostic Criteria for Tumour-Type-Specific Comprehensive Cachexia Risk.

Oncological and Survival Endpoints in Cancer Cachexia Clinical Trials: Systematic Review 6 of the Cachexia Endpoints Series.

In patients receiving anti-cancer treatment, cachexia results in poorer oncological outcomes. However, there is limited understanding and no systematic review of oncological endpoints in cancer cachexia (CC) trials. This review examines oncological endpoints in CC clinical trials. An electronic literature...

🗓️ 2025-04-01
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreOncological and Survival Endpoints in Cancer Cachexia Clinical Trials: Systematic Review 6 of the Cachexia Endpoints Series.

CACHEXIA DEFINITION

Cachexia has been defined as a loss of lean tissue mass, involving a weight loss greater than 5% of body weight in 12 months or less in the presence of chronic illness or as a body mass index (BMI) lower than 20 kg/m2. In addition, usually three of the following five criteria are required: decreased muscle strength, fatigue, anorexia, low fat-free mass index, increase of inflammation markers such as C-reactive protein or interleukin (IL)-6 as well as anaemia or low serum albumin.

Cachexia can occur in most major diseases including infections, cancer, heart disease, chronic kidney disease, chronic obstructive pulmonary disease, and stroke.

REFERENCES
Evans WJ, Morley JE, Argiles J, Bales C, Baracos V, Guttridge D, et al. Cachexia: a new definition. Clin Nutr 2008;27:793–799

Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, Davis M, Muscaritoli M, Ottery F, Radbruch L, Ravasco P, Walsh D, Wilcock A, Kaasa S, Baracos VE. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 2011;12:489–495.

Subscribe to the SCWD Newsletter

Stay Informed with the Latest Updates and Exclusive Insights!